Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

NCT02520102 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company has fulfilled post-marketing requirements

Conditions

Acute Myeloid Leukemia NOS

Interventions

DRUG: sargramostim GZ402664

Sponsor

Sanofi